Compare ELUT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | NRXP |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 54.2M |
| IPO Year | 2020 | N/A |
| Metric | ELUT | NRXP |
|---|---|---|
| Price | $1.09 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $31.50 |
| AVG Volume (30 Days) | 189.1K | ★ 497.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,375,000.00 | N/A |
| Revenue This Year | $26.95 | N/A |
| Revenue Next Year | $24.84 | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $1.58 |
| 52 Week High | $3.46 | $3.84 |
| Indicator | ELUT | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 49.93 |
| Support Level | $0.86 | $1.65 |
| Resistance Level | $1.39 | $1.99 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 25.00 | 63.49 |
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.